773887-07-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-isopropyl-6-methylaniline is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4-broMo-2-isopropyl-6-Methylaniline serves as an intermediate for the production of various agrochemicals. Its role in this industry is crucial for the development of effective pesticides and other agricultural products.
Used in Dye and Pigment Manufacturing:
4-Bromo-2-isopropyl-6-methylaniline is also employed in the manufacturing of dyes and pigments. Its chemical properties make it suitable for creating a wide range of colors and hues, which are used in various applications such as textiles, plastics, and printing inks.

Upstream product

• 5266-85-3 2-isopropyl-6-methylaniline 

Downstream Products

• 943827-02-9 4-[4-(4-bromo-2-isopropyl-6-methylphenylamino)pyrimidin-4-ylamino]benzonitrile 
• 773887-13-1 C₂₂H₂₃N₃O₄ 
• 773887-09-5 5-bromo-7-isopropyl-1H-indazole 

Relevant academic research and scientific papers

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and

Heteroaryl substituted 1, 2, 4-triazin-3-amine derivative , preparation method and application thereof in medicine

The present invention relates to a heteroaryl substituted 1, 2, 4-triazin-3-amine derivative, a preparation method thereof and an application thereof in medicine. In particular, the invention relatesto the heteroaryl substituted 1, 2, 4-triazin-3-amine de

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains

Novel diarylpyrimidines (DAPY), which represent next generation of non-nucleoside reverse transcriptase inhibitors (NNRTIs), were synthesized and their activities against human immunodeficiency virus type I (HIV-1) assessed. Modulations at positions 2 and

SUBSTITUTED ISOQUINOLINONES

Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.